Plant patents at the EPO - is an amended EU Biotech Directive (98/44/EC) on the horizon?

Plant patents at the EPO - is an amended EU Biotech Directive (98/44/EC) on the horizon?

By Jim Robertson - Patent Attorney | Partner

The saga of plant patents at the EPO continues - do recent events at the EPO and the European Commission suggest that there will be an attempt to amend the EU Biotech Directive 98/44/EC?

Following on from our December 2018 article reporting that an EPO Board of Appeal had found that plants are patentable at the EPO (i.e. that Rule 28(2) EPC is unenforceable), there have been two further developments.

  • Firstly, on 20 February 2019 the EPO issued a notice stating that the Administrative Council's Committee on Patent Law (CPL) "had a first exchange of views on possible next steps following the recent decision T 1063/18" and that it "supported measures to obtain an opinion from the Enlarged Board of Appeal on the matter.
  • Secondly, in a 7 March 2019 answer to a question from MEP Jan Huitema, the European Commission stated that "It also stands ready to engage in discussions on this issue with the European Parliament".

It would be extremely surprising if the EPO's Enlarged Board of Appeal allowed itself to be drawn into this political issue, especially since it has already given its opinion on the legal issue in decisions G2/12  ("Broccoli II") and G2/13  ("Tomatoes II"). In those two decisions, it found that Article 53(b) EPC does not exclude product claims directed to plants or plant material from patentability, even if made by an "essentially biological process" (which itself is excluded from patentability).

What is actually happening?

The fundamental issue here is whether or not Directive 98/44/EC bars the patenting of plants and plant material produced by "essentially biological processes". Many EU governments seem to be clear that they want them excluding from patentability. However, the EPO's Enlarged Board of Appeal has found in decisions G2/12 and G2/13 (above) that the European Patent Convention does not exclude them from patentability.

This limited the options available to the EPO's Administrative Council (i.e. the representatives of EPC contracting states, including all EU member states) and resulted in the seemingly inevitable failure of their attempt to change EPO practice by introducing new Rule 28(2) EPC (see our July 2017 article).

A Dutch court (the Court of Appeal of The Hague in its 28 May 2013 decision in case no.: 200.103.492/01 (Taste of Nature Holding B.V. vs. Cresco Handels B.V.)) found that the products of essentially biological processes for the production of plants are not excluded from patentability by Article 4(1)(b) of Directive 98/44/EC.

This could be resolved if the CJEU issued a decision on this issue. However, we are not aware of any currently pending cases, and there is a very real risk that the CJEU could decide that Directive 98/44/EC does not bar the patenting of plants and plant material produced by "essentially biological processes".

Significance of the recent events

The 20 February notice (above) from the EPO and the European Commission's 7 March answer (above) might signal that we are seeing a coordinated political effort from EU member states via the EPO Administrative Council and the European Parliament. It may be that they are seeking to exhaust all options at the EPO so that the matter can then be presented to the European Parliament as absolutely requiring its attention.

The European Parliament could then move to resolve things by passing a new Directive amending the Biotech Directive (Directive 98/44/EC) (see Joint Practical Guide at 18.6) to bar the patenting in the EU of plants and plant material produced by "essentially biological processes".

What would happen if the European Parliament amended the Biotech Directive?

Article 33(1)(b) EPC allows the Administrative Council to amend the European Patent Convention "... to bring [it] into line with an international treaty relating to patents or European Community legislation relating to patents". This requires the unanimity of all EPC contracting states and no abstentions (Article 35(3) and (4) EPC).

Therefore, once legislation amending Directive 98/44/EC entered into force (and not before - Article 33(5) EPC), the EPO Administrative Council could then use the provisions of Article 33(1)(b) EPC to amend the European Patent Convention itself (rather than amending the Implementing Regulations as it previously did when it introduced new Rule 28(2) EPC).

This would then sidestep the Enlarged Board of Appeal's decisions G2/12 and G2/13 (above), legitimise Rule 28(2) EPC, and block the patenting at the EPO of plants and plant material produced by essentially biological processes.

Conclusions and recommendations

Although amending Directive 98/44/EC and using that as the basis to amend the EPC could take a number of years, it would be a final resolution to the whole issue.

We will now have to wait to see what EU politicians decide to do - will they try to amend Directive 98/44/EC?

For patent applicants, it may well be worth seeking to accelerate prosecution of affected patent applications to try and pre-empt any future changes to the Biotech Directive and the EPC - the EPO President previously suspended prosecution of affected cases, and if EU law is to change then that might be done again.

If you have any questions regarding this then please contact your usual Wynne-Jones attorney.

Related News

US Inventor Declarations and Assignments
news

US Inventor Declarations and Assignments

After a patent application has been filed, the inventor may be required to sign and submit various forms.  What happens if this is several years into the patent process, and the inventor can no longer be reached to sign these forms?  And what can you do now to prevent any complications from arising?

UKIPO ending temporary fee changes on 31 March 2021
news

UKIPO ending temporary fee changes on 31 March 2021

The UK Intellectual Property Office (UK IPO) temporarily reduced or removed certain official fees associated with patents, trade marks and registered designs because of the disruption caused by the Coronavirus pandemic. However, the temporary fee changes are set to end on 31 March 2021.

Insurance for IP Litigation Costs
news

Insurance for IP Litigation Costs

If you own any intellectual property (IP) rights, are you concerned about your exposure to litigation, and how you will finance any legal action?  One way to address this concern is by means of an insurance policy.

Does owning IP rights improve economic performance?
news

Does owning IP rights improve economic performance?

A recent study performed by the European Patent Office (EPO) and the European Union Intellectual Property Office (EUIPO) has shown that companies which own at least one patent, trade mark or registered design generate on average 20% higher revenues per employee and pay their staff on average 19% higher wages compared to companies that do not own any of these intellectual property (IP) rights.

Let it go!
news

Let it go!

Keeping an IP budget afloat despite sunk costs.

The cost of securing IP can be heavily front loaded. Examples of such costs include patent drafting, pre-filing searches, filing fees, etc. These costs become “sunk” costs in that they cannot be recovered. Because IP protection can be a relatively long process, at any time during the process there are likely to be significant “prospective” costs: future costs that may be wholly or partially avoided depending on actions taken.

Turkish Declarations of Use
news

Turkish Declarations of Use

Have you recently validated your European patent in Turkey?  Did you know that in addition to paying annual renewal fees, Turkish law also requires you to submit a public declaration stating whether you have actively worked your invention in Turkey?

Managing your business-critical IP during the COVID-19 crisis
news

Managing your business-critical IP during the COVID-19 crisis

UK businesses are fighting for survival during the continuing COVID-19 outbreak and trying to trade under difficult conditions, the likes of which haven’t been seen in the living memory of most business people. If you’re afraid that your business is going to the wall, it probably isn’t the top of your mind to pay for a patent application for your new technology or a registration of the trade mark for your brand new clothing range, right?  Where is the money coming from to invest in such luxuries as IP, we hear you say, when staff are being furloughed and orders have been postponed?

Videoconferencing: the future of oral proceedings at the EPO?
news

Videoconferencing: the future of oral proceedings at the EPO?

The European Patent Office has announced that videoconferencing will become the norm for oral proceedings before examination and opposition divisions until at least 15 September 2021. But is this a taste of what the future holds for oral proceedings at the EPO?

aipex logo aipex logo aipex logo